Cancer stem cells and hepatocellular carcinoma

Cancer Biology and Therapy

Volumn 8, Issue 18, 2009, Pages 1691-1698

  Yao, Zhixing ^a   Mishra, Lopa ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

2 SPECTRIN; Hepatocellular cancer; Signal transduction; Stem progenitor cells; TGF

Indexed keywords

NOTCH RECEPTOR; SONIC HEDGEHOG PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

CANCER STEM CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; DNA REPLICATION; EPIGENETICS; GENE EXPRESSION; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

EID: 73249127416     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.18.9843     Document Type: Review

References (100)

1. Lin L, Amin R, Gallicano GI, Glasgow E, Jogunoori W, Jessup JM, et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGFbeta signaling. Oncogene 2009; 28:961-72.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009; 59:225-49.
3. Mishra L, Banker T, Murray J, Byers S, Thenappan A, He AR, et al. Liver stem cells and hepatocellular carcinoma. Hepatology 2009; 49:318-29.
4. Mishra L, Derynck R, Mishra B. Transforming growth factor-beta signaling in stem cells and cancer. Science 2005; 310:68-71.
5. Tang Y, Kitisin K, Jogunoori W, Li C, Deng CX, Mueller SC, et al. Progenitor/stem cells give rise to liver cancer due to aberrant TGFbeta and IL-6 signaling. Proc Natl Acad Sci USA 2008; 105:2445-50.
6. Rando TA. The immortal strand hypothesis: segregation and reconstruction. Cell 2007; 129:1239-43.
7. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer and cancer stem cells. Nature 2001; 414:105-11.
8. Tsai RY. A molecular view of stem cell and cancer cell self-renewal. Int J Biochem Cell Biol 2004; 36:684-94.
9. Rossi DJ, Jamieson CH, Weissman IL. Stems cells and the pathways to aging and cancer. Cell 2008; 132:681-96.
10. Morrison SJ, Kimble J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 2006; 441:1068-74.
11. Morrison SJ, Spradling AC. Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell 2008; 132:598-611.
12. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003; 3:895-902.
13. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008; 456:593-8.
14. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126:663-76.
15. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008; 322:949-53.
16. Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science 2008; 322:945-9.
17. Tang Y, Katuri V, Dillner A, Mishra B, Deng CX, Mishra L. Disruption of transforming growth factor-beta signaling in ELFbeta-spectrin-deficient mice. Science 2003; 299:574-7.
18. Fausto N. Liver regeneration and repair: hepatocytes, progenitor cells and stem cells. Hepatology 2004; 39:1477-87.
19. Michalopoulos GK, DeFrances MC. Liver regeneration. Science 1997; 276:60-6.
20. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 2006; 25:3818-22.
21. Weinstein M, Monga SP, Liu Y, Brodie SG, Tang Y, Li C, et al. Smad proteins and hepatocyte growth factor control parallel regulatory pathways that converge on beta1-integrin to promote normal liver development. Mol Cell Biol 2001; 21:5122-31.
22. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006; 44:240-51.
23. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch Signaling: Cell Fate Control and Signal Integration in Development. Science 1999; 284:770-6.
24. Artavanis-Tsakonas S, Matsuno K, Fortini ME. Notch signaling. Science 1995; 268:225-32.
25. Androutsellis-Theotokis A, Leker RR, Soldner F, Hoeppner DJ, Ravin R, Poser SW, et al. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature 2006; 442:823-6.
26. Tien AC, Rajan A, Bellen HJ. A Notch updated. J Cell Biol 2009; 184:621-9.
27. Weng AP, Aster JC. Multiple niches for Notch in cancer: context is everything. Curr Opin Genet Dev 2004; 14:48-54.
28. Giovannini C, Lacchini M, Gramantieri L, Chieco P, Bolondi L. Notch3 intracellular domain accumulates in HepG2 cell line. Anticancer Res 2006; 26:2123-7.
29. Gramantieri L, Giovannini C, Lanzi A, Chieco P, Ravaioli M, Venturi A, et al. Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. Liver Int 2007; 27:997-1007.
30. Gao J, Chen C, Hong L, Wang J, Du Y, Song J, et al. Expression of Jagged1 and its association with hepatitis B virus X protein in hepatocellular carcinoma. Biochem Biophys Res Commun 2007; 356:341-7.
31. Fitzgerald K, Harrington A, Leder P. Ras pathway signals are required for notch-mediated oncogenesis. Oncogene 2000; 19:4191-8.
32. Gonsalves FC, Weisblat DA. MAPK regulation of maternal and zygotic Notch transcript stability in early development. Proc Natl Acad Sci USA 2007; 104:531-6.
33. Stockhausen MT, Sjolund J, Axelson H. Regulation of the Notch target gene Hes-1 by TGFalpha induced Ras/MAPK signaling in human neuroblastoma cells. Exp Cell Res 2005; 310:218-28.
34. Chappell WH, Green TD, Spengeman JD, McCubrey JA, Akula SM, Bertrand FE. Increased protein expression of the PTEN tumor suppressor in the presence of constitutively active Notch-1. Cell Cycle 2005; 4:1389-95.
35. Qi R, An H, Yu Y, Zhang M, Liu S, Xu H, et al. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res 2003; 63:8323-9.
36. Wang C, Qi R, Li N, Wang Z, An H, Zhang Q, et al. Notch1 signaling sensitizes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and upregulating p53-dependent DR5 expression. J Biol Chem 2009; 284:16183-90.
37. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005; 434:843-50.
38. Shimizu H, Julius MA, Giarre M, Zheng Z, Brown AM, Kitajewski J. Transformation by Wnt family proteins correlates with regulation of beta-catenin. Cell Growth Differ 1997; 8:1349-58.
39. Hatsell S, Rowlands T, Hiremath M, Cowin P. Beta-catenin and Tcfs in mammary development and cancer. J Mammary Gland Biol Neoplasia 2003; 8:145-58.
40. Nusse R, van Ooyen A, Cox D, Fung YK, Varmus H. Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15. Nature 1984; 307:131-6.
41. Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors and multiple transcription factors. J Biol Chem 2006; 281:22429-33.
42. Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW. Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J Biol Chem 1997; 272:24735-8.
43. Cook D, Fry MJ, Hughes K, Sumathipala R, Woodgett JR, Dale TC. Wingless inactivates glycogen synthase kinase-3 via an intracellular signalling pathway which involves a protein kinase C. EMBO J 1996; 15:4526-36.
44. Chen RH, Ding WV, McCormick F. Wnt signaling to beta-catenin involves two interactive components. Glycogen synthase kinase-3beta inhibition and activation of protein kinase C. J Biol Chem 2000; 275:17894-9.
45. Kim D, Rath O, Kolch W, Cho KH. A hidden oncogenic positive feedback loop caused by crosstalk between Wnt and ERK pathways. Oncogene 2007; 26:4571-9.
46. Xie Z, Yuan H, Yin Y, Zeng X, Bai R, Glazer RI. 3-phosphoinositide- dependent protein kinase-1 (PDK1) promotes invasion and activation of matrix metalloproteinases. BMC Cancer 2006; 6:77.
47. Zeng X, Xu H, Glazer RI. Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase Calpha. Cancer Res 2002; 62:3538-43.
48. Li Y, Welm B, Podsypanina K, Huang S, Chamorro M, Zhang X, et al. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci USA 2003; 100:15853-8.
49. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001; 411:349-54.
50. Clarke AR. Wnt signalling in the mouse intestine. Oncogene 2006; 25:7512-21.
51. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001; 120:1763-73.
52. Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, et al. Mutational spectrum of beta-catenin, AXIN1 and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002; 21:4863-71.
53. Ishizaki Y, Ikeda S, Fujimori M, Shimizu Y, Kurihara T, Itamoto T, et al. Immunohistochemical analysis and mutational analyses of beta-catenin, Axin family and APC genes in hepatocellular carcinomas. Int J Oncol 2004; 24:1077-83.
54. Park JY, Park WS, Nam SW, Kim SY, Lee SH, Yoo NJ, et al. Mutations of beta-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis. Liver Int 2005; 25:70-6.
55. Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000; 24:245-50.
56. Merle P, de la Monte S, Kim M, Herrmann M, Tanaka S, Von Dem Bussche A, et al. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology 2004; 127:1110-22.
57. Prange W, Breuhahn K, Fischer F, Zilkens C, Pietsch T, Petmecky K, et al. Beta-catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E-cadherin and accumulation of p53, but not with expression of conventional WNT-1 target genes. J Pathol 2003; 201:250-9.
58. Inagawa S, Itabashi M, Adachi S, Kawamoto T, Hori M, Shimazaki J, et al. Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res 2002; 8:450-6.
59. Joo M, Lee HK, Kang YK. Expression of beta-catenin in hepatocellular carcinoma in relation to tumor cell proliferation and cyclin D1 expression. J Korean Med Sci 2003; 18:211-7.
60. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003; 423:409-14.
61. Murdoch B, Chadwick K, Martin M, Shojaei F, Shah KV, Gallacher L, et al. Wnt-5A augments repopulating capacity and primitive hematopoietic development of human blood stem cells in vivo. Proc Natl Acad Sci USA 2003; 100:3422-7.
62. Pitsouli C, Perrimon N. Developmental biology: Our fly cousins' gut. Nature 2008; 454:592-3.
63. Bardeesy N, Cheng KH, Berger JH, Chu GC, Pahler J, Olson P, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 2006; 20:3130-46.
64. Weinstein M, Yang X, Deng C. Functions of mammalian Smad genes as revealed by targeted gene disruption in mice. Cytokine Growth Factor Rev 2000; 11:49-58.
65. Chang H, Brown CW, Matzuk MM. Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocr Rev 2002; 23:787-823.
66. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer and heritable disorders. Cell 2000; 103:295-309.
67. Mishra L, Cai T, Yu P, Monga SP, Mishra B. β2-Spectrin3 encodes a novel 200-kD beta-spectrin: role in liver development. Oncogene 1999; 18:353-64.
68. Monga SP, Tang Y, Candotti F, Rashid A, Wildner O, Mishra B, et al. Expansion of hepatic and hematopoietic stem cells utilizing mouse embryonic liver explants. Cell Transplant 2001; 10:81-9.
69. Blake T, Ganesan N, Shetty K, Mishra L. TGFbeta Signaling in Gastrointestinal Stem Cells. Sci STKE (Connections Map, as seen September 2005; http://stke.sciencemag.org/cgi/cm/stkecm;CMP-17699).
70. Feng XH, Derynck R. Specificity and versatility in TGFbeta signaling through Smads. Annu Rev Cell Dev Biol 2005; 21:659-93.
71. Roberts A, Mishra L. Role of TGFbeta in stem cells and cancer. Oncogene 2005; 24:5667.
72. Antequera F. Genomic specification and epigenetic regulation of eukaryotic DNA replication origins. EMBO J 2004; 23:4365-70.
73. McNairn AJ, Gilbert DM. Epigenomic replication: linking epigenetics to DNA replication. Bioessays 2003; 25:647-56.
74. Méchali M. DNA replication origins: from sequence specificity to epigenetics. Nat Rev Genet 2001; 2:640-5.
75. Pasero P, Bensimon A, Schwob E. Single-molecule analysis reveals clustering and epigenetic regulation of replication origins at the yeast rDNA locus. Genes Dev 2002; 16:2479-84.
76. Stedman W, Deng Z, Lu F, Lieberman PM. ORC MCM, and histone hyperacetylation at the Kaposi's sarcoma-associated herpesvirus latent replication origin. J Virol 2004; 78:12566-75.
77. Zhou J, Chau CM, Deng Z, Shiekhattar R, Spindler MP, Schepers A, et al. Cell cycle regulation of chromatin at an origin of DNA replication. EMBO J 2005; 24:1406-17.
78. Wu R, Terry AV, Singh PB, Gilbert DM. Differential subnuclear localization and replication timing of histone H3 lysine 9 methylation states. Mol Biol Cell 2005; 16:2872-81.
79. Hendrich B, Tweedie S. The methyl-CpG binding domain and the evolving role of DNA methylation in animals. Trends Genet 2003; 19:269-77.
80. Cohen SM, Brylawski BP, Cordeiro-Stone M, Kaufman DG. Same origins of DNA replication function on the active and inactive human X chromosomes. J Cell Biochem 2003; 88:923-31.
81. Gómez M, Brockdorff N. Heterochromatin on the inactive X chromosome delays replication timing without affecting origin usage. Proc Natl Acad Sci USA 2004; 101:6923-7298.
82. Goto Y, Gomez M, Brockdorff N, Feil R. Differential patterns of histone methylation and acetylation distinguish active and repressed alleles at X-linked genes Cytogenet Genome Res 2002; 99:66-74.
83. Wong N, Lam WC, Lai PB, Pang E, Lau WY, Johnson PJ. Hypomethylation of chromosome 1 heterochromatin DNA correlates with q-arm copy gain in human hepatocellular carcinoma. Am J Pathol 2001; 159:465-671.
84. Lee CF, Ling ZQ, Zhao T, Fang SH, Chang WC, Lee SC, et al. Genomic-wide analysis of lymphatic metastasis-associated genes in human hepatocellular carcinoma. World J Gastroenterol 2009; 15:356-65.
85. Bastian PJ, Ellinger J, Heukamp LC, Kahl P, Müller SC, von Rücker A. Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur Urol 2007; 51:665-74.
86. Ting AH, et al. The cancer epigenome-components and functional correlates. Genes Dev 2006; 20:3215-31.
87. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393:386-9.
88. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683-92.
89. INK4 (MTS1) gene inactivation in testicular germ cell tumors. Am J Pathol 1997; 151:859-65.
90. Yoshikawa H, Matsubara K, Qian GS, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001; 28:29-35.
91. Shikauchi Y, Saiura A, Kubo T, Niwa Y, Yamamoto J, Murase Y, et al. SALL3 interacts with DNMT3A and shows the ability to inhibit CpG island methylation in hepatocellular carcinoma. Mol Cell Biol 2009; 29:1944-58.
92. Iliopoulos D, Satra M, Drakaki A, Poultsides GA, Tsezou A. Epigenetic regulation of hTERT promoter in hepatocellular carcinomas. Int J Oncol 2009; 34:391-9.
93. Spira AI, Carducci MA. Differentiation therapy. Curr Opin Pharmacol 2003; 3:338-43.
94. Miletti-Gonzalez KE, Chen S, Muthukumaran N, Saglimbeni GN, Wu X, Yang J, et al. The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res 2005; 65:6660-7.
95. Massard C, Deutsch E, Soria JC. Tumour stem cell-targeted treatment: elimination or differentiation. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 2006; 17:1620.
96. Endo Y, Deonauth K, Prahalad P, Hoxter B, Zhu Y, Byers SW. Role of Sox-9, ER81 and VE-cadherin in retinoic acid-mediated trans-differentiation of breast cancer cells. PLoS ONE 2008; 3:2714.
97. Adams GB, Martin RP, Alley IR, Chabner KT, Cohen KS, Calvi LM, et al. Therapeutic targeting of a stem cell niche. Nature Biotech 2007; 25:238.
98. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425:841.
99. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003; 425:836-41.
100. Martinez-Iglesias O, Ruiz-Llorente L, Sanchez-Martinez R, Garcia L, Zambrano A, Aranda A. Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clin Transl Oncol 2008; 10:395-8.